Causality Assessment Guidelines for Adverse Events Following Immunization with a Focus on Guillain-Barre Syndrome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hankil | - |
dc.contributor.author | Kang, Hye-Young | - |
dc.contributor.author | Cho, Sunghwa | - |
dc.contributor.author | Park, Seonyoung | - |
dc.contributor.author | Kim, Ah-Young | - |
dc.contributor.author | Jung, Sun-Young | - |
dc.contributor.author | Seong, Baik Lin | - |
dc.contributor.author | Lee, Young-Mock | - |
dc.date.available | 2020-08-04T02:20:49Z | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 2076-393X | - |
dc.identifier.issn | 2076-393X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/42804 | - |
dc.description.abstract | South Korea operates a National Vaccine Injury Compensation Program (VICP) for people who experience adverse events following immunization (AEFI). To run this program rationally, it is a prerequisite to confirm whether adverse events were caused by immunization. Guillain-Barre syndrome (GBS), a severe neurological disease with limb pain and muscle weakness as cardinal symptoms, is attracting attention as an AEFI. However, algorithm or guidelines for assessing the causality between vaccination and the incidence of GBS are lacking. We aimed to develop guidelines for causality assessment of GBS as an AEFI and suggest using these guidelines in alignment with the VICP. We systematically searched for other previously published algorithms or guidelines and found a WHO-AEFI guideline used worldwide; however, it only provides general instructions and is not tailored to specific adverse events. We translated and locally adapted the structure of this guideline and then added contents related to GBS. The GBS-specific guideline consists of four steps: case ascertainment of GBS, checklist (including (1) order of incidence, (2) temporal proximity, (3) evidence for other causes and (4) published evidence), an algorithm, and final classification. We listed key information on confirming GBS and whether any other causes of GBS were present. For real world application of the guideline along with the VICP, we collaborated with a panel of neurologists, epidemiologic investigators, and committee members from the VICP. To ensure transparency and a scientific approach, regular updates and collaboration with neurologists are essential. We expect that this guideline will contribute to logical causality assessment and compensation decisions for GBS and will provide the basic structure for causality assessment of other AEFIs. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | Causality Assessment Guidelines for Adverse Events Following Immunization with a Focus on Guillain-Barre Syndrome | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/vaccines8010101 | - |
dc.identifier.bibliographicCitation | VACCINES, v.8, no.1 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000529439800100 | - |
dc.identifier.scopusid | 2-s2.0-85079876382 | - |
dc.citation.number | 1 | - |
dc.citation.title | VACCINES | - |
dc.citation.volume | 8 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | adverse event | - |
dc.subject.keywordAuthor | causality assessment | - |
dc.subject.keywordAuthor | guideline | - |
dc.subject.keywordAuthor | Guillain-Barre syndrome | - |
dc.subject.keywordAuthor | vaccine | - |
dc.subject.keywordPlus | CYTOMEGALOVIRUS-INFECTION | - |
dc.subject.keywordPlus | CAMPYLOBACTER-JEJUNI | - |
dc.subject.keywordPlus | DRUG-REACTIONS | - |
dc.subject.keywordPlus | VACCINATION | - |
dc.subject.keywordPlus | PATHOGENESIS | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | DEFINITIONS | - |
dc.subject.keywordPlus | ALGORITHM | - |
dc.subject.keywordPlus | SURGERY | - |
dc.subject.keywordPlus | VIRUS | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.